Crinetics Pharmaceuticals (CRNX) News Today $54.72 -4.94 (-8.28%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period What is HC Wainwright's Forecast for CRNX FY2024 Earnings?November 16 at 2:19 AM | americanbankingnews.comCrinetics Pharmaceuticals to Participate in Three Upcoming December Investor ConferencesNovember 15 at 11:34 PM | markets.businessinsider.comHC Wainwright Issues Pessimistic Forecast for CRNX EarningsCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) - Analysts at HC Wainwright lowered their FY2024 earnings per share (EPS) estimates for Crinetics Pharmaceuticals in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst D. Tsao now expects that the company willNovember 15 at 7:14 AM | marketbeat.comFY2024 Earnings Forecast for CRNX Issued By Lifesci CapitalCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) - Stock analysts at Lifesci Capital lowered their FY2024 earnings per share estimates for shares of Crinetics Pharmaceuticals in a report issued on Tuesday, November 12th. Lifesci Capital analyst C. Jubinville now expects that the companNovember 15 at 7:14 AM | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Sets New 1-Year High Following Analyst UpgradeNovember 15 at 2:25 AM | americanbankingnews.comUPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual MeetingNovember 14 at 4:05 PM | globenewswire.comCrinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 14 at 1:19 PM | tmcnet.comCrinetics Pharmaceuticals: Promising Future with Innovative Drug Developments and Strong Financial PositionNovember 14 at 1:19 PM | markets.businessinsider.comPositive Outlook for Crinetics Pharmaceuticals: Strategic Advancements and Strong Financial Position Drive Target Price IncreaseNovember 14 at 1:19 PM | markets.businessinsider.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Rating of "Moderate Buy" by BrokeragesNovember 14 at 3:01 AM | americanbankingnews.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eleven brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and ten have assNovember 14 at 2:58 AM | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPSCrinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.05). During the same period last year, the firm posted ($1.01) EPS.November 13, 2024 | marketbeat.comCrinetics Pharmaceuticals: Advancing Cancer Treatment with Novel NDC Platform – A Buy RecommendationNovember 13, 2024 | markets.businessinsider.comCrinetics Pharmaceuticals Announces Q3 2024 Financial ResultsNovember 13, 2024 | markets.businessinsider.comCrinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...November 13, 2024 | finance.yahoo.comCrinetics Pharmaceuticals, Inc. (CRNX) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comCrinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual MeetingNovember 12, 2024 | globenewswire.comCrinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 12, 2024 | globenewswire.comCrinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 12, 2024 | markets.businessinsider.comCrinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 11, 2024 | globenewswire.comLisanti Capital Growth LLC Purchases 25,195 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Lisanti Capital Growth LLC lifted its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 30.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 108,575 shares of the company's stock after purchasing an additional 25,195 sharNovember 11, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Fiera Capital CorpFiera Capital Corp decreased its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 3.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 466,075 shares of the company's stock after selling 14,334 shares duNovember 9, 2024 | marketbeat.comCrinetics Pharmaceuticals (CRNX) to Release Earnings on TuesdayCrinetics Pharmaceuticals (NASDAQ:CRNX) will be releasing earnings after the market closes on Tuesday, November 12, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=636105)November 5, 2024 | marketbeat.comabrdn plc Cuts Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)abrdn plc reduced its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 46.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 35,467 shares of the company's stock after sellinNovember 5, 2024 | marketbeat.comInvestors might be losing patience for Crinetics Pharmaceuticals' (NASDAQ:CRNX) increasing losses, as stock sheds 5.6% over the past weekOctober 30, 2024 | finance.yahoo.comCrinetics Pharmaceuticals: Strong Buy Recommendation Driven by Best-in-Class Efficacy and Solid Financial PositionOctober 24, 2024 | markets.businessinsider.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock Position Cut by Moody Aldrich Partners LLCMoody Aldrich Partners LLC trimmed its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 7.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 139,130 shares of the company'sOctober 24, 2024 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 1-Year High - Here's What HappenedCrinetics Pharmaceuticals (NASDAQ:CRNX) Sets New 1-Year High - Time to Buy?October 22, 2024 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Sets New 1-Year High - Should You Buy?Crinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 12-Month High - What's Next?October 16, 2024 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Shares Up 4.4% - Still a Buy?Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Up 4.4% - What's Next?October 15, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Sees Large Growth in Short InterestCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) was the recipient of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 6,780,000 shares, an increase of 11.0% from the September 15th total of 6,110,000 shares. Based on an average daily trading volume, of 655,400 shares, the short-interest ratio is currently 10.3 days.October 15, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock Position Lowered by SG Americas Securities LLCSG Americas Securities LLC lowered its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 83.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,963 shares of the companyOctober 14, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 12, 2024 | finanznachrichten.deCrinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 10, 2024 | globenewswire.comCrinetics Pharmaceuticals Selling Up to $460M in SharesOctober 10, 2024 | marketwatch.comCrinetics Pharma Prices Public Offering Of 10 Mln Shares At $50/ShrOctober 10, 2024 | markets.businessinsider.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Sees Large Volume Increase - Still a Buy?Crinetics Pharmaceuticals (NASDAQ:CRNX) Sees Large Volume Increase - Time to Buy?October 9, 2024 | marketbeat.comCrinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common StockOctober 8, 2024 | globenewswire.comCrinetics Pharmaceuticals Announces Proposed Public Offering of Common StockOctober 8, 2024 | globenewswire.comDana Pizzuti Sells 14,375 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) StockOctober 8, 2024 | insidertrades.comThe Manufacturers Life Insurance Company Increases Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)The Manufacturers Life Insurance Company boosted its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 21.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 131,063 shares of the company's stock after buyinOctober 7, 2024 | marketbeat.comEnvestnet Asset Management Inc. Raises Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Envestnet Asset Management Inc. lifted its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 23.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 51October 5, 2024 | marketbeat.comDimensional Fund Advisors LP Has $24.49 Million Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Dimensional Fund Advisors LP lowered its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 14.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 546,759 sharesOctober 4, 2024 | marketbeat.comInsider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) CFO Sells 25,000 Shares of StockOctober 1, 2024 | insidertrades.comMarshall Wace LLP Takes Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Marshall Wace LLP bought a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) in the second quarter, according to its most recent filing with the SEC. The firm bought 141,204 shares of the company's stock, valued at approximately $6,325,000. Marshall Wace LLP owned approximOctober 1, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Holdings Lowered by Novo Holdings A SNovo Holdings A S lowered its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 9.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,000,000 shares of the company's stock afterSeptember 30, 2024 | marketbeat.comCrinetics Pharmaceuticals submits new acromegaly drug NDASeptember 28, 2024 | investing.comGuru Fundamental Report for CRNXSeptember 28, 2024 | nasdaq.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stake Increased by Driehaus Capital Management LLCDriehaus Capital Management LLC raised its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 17.0% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,112,173 shares of the compSeptember 28, 2024 | marketbeat.comBuy Rating on Crinetics Pharmaceuticals Amidst Paltusotine’s Promising Market Disruption PotentialSeptember 27, 2024 | markets.businessinsider.com Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address The Tesla Trade Is Back In Business (Ad)If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla. Discover how to trade Tesla, simply follow this link here. CRNX Media Mentions By Week CRNX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRNX News Sentiment▼0.160.56▲Average Medical News Sentiment CRNX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRNX Articles This Week▼306▲CRNX Articles Average Week Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ionis Pharmaceuticals News Today Avadel Pharmaceuticals News Today Bicycle Therapeutics News Today Moderna News Today Viatris News Today Summit Therapeutics News Today Genmab A/S News Today Vaxcyte News Today Dr. Reddy's Laboratories News Today Sarepta Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRNX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRNX Stock Alerts